Inquire Before Buying - Non-Small Cell Lung Cancer(NSCLC) Market Grow CAGR of 11.2% by 2027

Global Non-Small Cell Lung Cancer Market Research Report: Forecast (2022-2027)

By Diagnosis (Blood & Urine Tests, Imaging, Biopsy, Sputum Cytology, Bronchoscopy), By Cancer Type (Squamous Cell Carcinoma (SCC), Large Cell Carcinoma (LCC), Adenocarcinoma), By T......reatment (Surgery, Chemotherapy, Immunotherapy (Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors, CTLA-4 Inhibitor)), Radiation Therapy (External Beam Radiation Therapy, Brachytherapy (Internal Radiation Therapy)), Radiofrequency Ablation (RFA), Targeted Therapy), By End-User (Hospitals, Cancer Centers, Others (Ambulatory Surgery Centers, etc.)), By Region (North America, South America, Europe, Middle East & Africa, Asia-Pacific), By Country (The US, Canada, Mexico, Brazil, the UK, Germany, France, Italy, Spain, South Africa, GCC, China, Japan, India, Australia, South East Asia) Read more

Healthcare
Jun 2022
Pages 189
Report Format: PDF, Excel, PPT

Market Definition

Non-Small Cell Lung Cancer (NSCLC) is the most common & epithelial type of lung cancer that occurs in different forms, viz., Squamous Cell Carcinoma (SCC), Large Cell Carcinoma (LCC), & Adenocarcinoma. Smoking is mainly responsible for NSCLC since smokers are more likely to develop NSCLC. However, it is observed that adenocarcinoma has also occurred in patients with no smoking history.

Further, as the prevalence of lung cancers is rising worldwide, the demand for their diagnosis & treatments is also surging rapidly, which, in turn, is compelling governments & leading biopharma companies to boost drug developments & distributions in order to cater to the unmet patient needs for efficient & safe NSCLC treatments.

Market Insights

The Global Non-Small Cell Lung Cancer (NSCLC) Market is projected to grow at a CAGR of around 11.2% during the forecast period, i.e., 2022-27. Most of the market growth would be driven by the growing number of patients with Non-Small Cell Lung Cancer (NSCLC) type of lung cancer and the mounting demand for its effective diagnosis & treatment worldwide.

Observing the growing influx of NSCLC patients globally, governments of different countries are investing massively in the healthcare sector to strengthen the oncology department, including the NSCLC, and encourage the leading biopharmaceutical companies to discover novel therapeutics with enhanced efficacy & safety. As a result, the expansion of various players and the emergence of local companies are seen extensively worldwide.

Report Coverage	Details
Study Period	Historical Data: 2017-20
	Base Year: 2021
	Forecast Period: 2022-27
CAGR (2022-2027)	11.2%
Regions Covered	North America: The US, Canada, Mexico
	South America: Brazil, Rest of South America
	Europe: Germany, The UK, France, Spain, Italy, Rest of Europe
	Asia-Pacific: China, Japan, India, South Korea, Rest of Asia Pacific
	Middle East & Africa: GCC, South Africa, Rest of Middle East and Africa
Key Companies Profiled	Allergan (AbbVie), AstraZeneca PLC, Boehringer Ingelheim, Bristol Myers Squibb, Eisai Co., Ltd, Eli Lilly and Company, GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, Other
Unit Denominations	USD Million/Billion

Additionally, growing awareness among people about the availability of diagnosis & various treatments for NSCLC through government engagement in campaigns, advertisements, etc., i.e., portraying a rising patient pool across different countries, is further augmenting the overall market growth.

The leading biotechnology & pharmaceutical companies like Pfizer Inc. are developing & introducing sophisticated targeted therapies like Vizimpra & Lorbrena for NSCLC patients, i.e., another crucial aspect projecting remunerative prospects for the Global Non-Small Cell Lung Cancer (NSCLC) Market through 2027.

Introduction
1. Research Process
2. Assumption
3. Market Segmentation
4. Market Definition
Executive Summary
Global Non-Small Cell Lung Cancer (NSCLC) Market Trends & Insights
Global Non-Small Cell Lung Cancer (NSCLC) Market Regulation & Policy, By Country
Global Non-Small Cell Lung Cancer (NSCLC) Market Dynamics
1. Growth Drivers
2. Challenges
3. Impact Analysis
Global Non-Small Cell Lung Cancer (NSCLC) Market Hotspot and Opportunities
Global Non-Small Cell Lung Cancer (NSCLC) Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
    1. Blood & Urine Tests
    2. Imaging
    3. Biopsy
    4. Sputum Cytology
    5. Bronchoscopy
  2. By Cancer Type
    1. Squamous Cell Carcinoma (SCC)
    2. Large Cell Carcinoma (LCC)
    3. Adenocarcinoma
  3. By Treatment
    1. Surgery
    2. Chemotherapy
    3. Immunotherapy
      1. Immune Checkpoint Inhibitors
        
        PD-1/PD-L1 Inhibitors
        
        CTLA-4 Inhibitor
    4. Radiation Therapy
      1. External Beam Radiation Therapy
      2. Brachytherapy (Internal Radiation Therapy)
    5. Radiofrequency Ablation (RFA)
    6. Targeted Therapy
  4. By End-User
    1. Hospitals
    2. Cancer Centers
    3. Others (Ambulatory Surgery Centers, etc.)
  5. By Region
    1. North America
    2. South America
    3. Europe
    4. Middle East & Africa
    5. Asia-Pacific
  6. By Company
    1. Competition Characteristics
    2. Revenue Shares
    3. Competitor Placement in MarkNtel Advisor’s Quadrant
North America Non-Small Cell Lung Cancer (NSCLC) Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
  2. By Cancer Type
  3. By Treatment
  4. By End-User
  5. By Country
    1. The US
    2. Canada
    3. Mexico
South America Non-Small Cell Lung Cancer (NSCLC) Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
  2. By Cancer Type
  3. By Treatment
  4. By End-User
  5. By Country
    1. Brazil
    2. Rest of Latin America
Europe Non-Small Cell Lung Cancer (NSCLC) Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
  2. By Cancer Type
  3. By Treatment
  4. By End-User
  5. By Country
    1. The UK
    2. Germany
    3. France
    4. Italy
    5. Spain
    6. Rest of Europe
Middle East & Africa Non-Small Cell Lung Cancer (NSCLC) Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
  2. By Cancer Type
  3. By Treatment
  4. By End-User
  5. By Country
    1. South Africa
    2. GCC
    3. Rest of Middle East & Africa
Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
  2. By Cancer Type
  3. By Treatment
  4. By End-User
  5. By Country
    1. China
    2. Japan
    3. India
    4. Australia
    5. South East Asia
    6. Rest of Asia Pacific
Global Non-Small Cell Lung Cancer (NSCLC) Market Key Strategic Imperatives for Success and Growth
Competitive Outlook
1. Competition Matrix
  1. By Application Portfolio
  2. Brand Specialization
  3. Target Markets
  4. Target by Applications
  5. Research & Development
  6. Strategic Alliances
  7. Strategic Initiatives
2. Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
  1. Allergan (AbbVie)
  2. AstraZeneca PLC
  3. Boehringer Ingelheim
  4. Bristol Myers Squibb
  5. Eisai Co., Ltd.
  6. Eli Lilly and Company
  7. GlaxoSmithKline PLC
  8. F. Hoffmann-La Roche AG
  9. Merck & Co., Inc.
  10. Novartis International AG
  11. Pfizer Inc.
  12. Sanofi S.A.
  13. Others
Disclaimer

MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

FILL THE FORM TO INQUIRE BEFORE BUYING THIS REPORT

Name *

Email ID *

Country *